Exelixis, Inc. (EXEL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Exelixis, Inc. (EXEL) Healthcare & Pipeline Overview

Exelixis, Inc. is a biotechnology company focused on oncology, developing and commercializing treatments like CABOMETYX and COMETRIQ. Their kinase inhibitor-based therapies target cancers, positioning them as a key player in the oncology drug market with ongoing research collaborations and a robust pipeline.

What Is the Investment Thesis for EXEL?

CABOMETYX, a key revenue driver, continues to demonstrate strong performance in the renal cell carcinoma market. The company's robust gross margin of 96.4% indicates efficient operations and pricing power. Upcoming clinical trial results for XL092 and XB002 could serve as significant catalysts, expanding the company's therapeutic reach. However, potential risks include clinical trial failures and increased competition in the oncology space. With a P/E ratio of 17.46, Exelixis appears reasonably valued relative to its growth prospects. Continued success in expanding indications for existing products and advancing its pipeline are critical for sustained growth.

Based on FMP financials and quantitative analysis

EXEL Key Highlights

Market Cap of $14.5B reflects investor confidence in Exelixis' oncology-focused strategy and product portfolio.

• P/E ratio of 17.46 suggests a reasonable valuation compared to its biotechnology peers.
• Profit Margin of 35.1% indicates strong profitability and efficient cost management.
• Gross Margin of 96.4% demonstrates significant pricing power and efficient manufacturing processes.
• Beta of 0.42 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.

Who Are EXEL's Competitors?

EXEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EXEL's Key Strengths?

Established product portfolio with CABOMETYX and COMETRIQ.

• Strong gross margins and profitability.
• Robust pipeline of new drug candidates.
• Strategic collaborations with leading pharmaceutical companies.

What Are EXEL's Weaknesses?

Reliance on a limited number of key products.

• Exposure to clinical trial risks.
• Dependence on regulatory approvals.
• Geographic concentration in the United States and Japan.

What Could Drive EXEL Stock Higher?

Clinical trial results for XL092 in various cancer types expected in late 2027.

• Regulatory submissions for new indications of CABOMETYX.
• Expansion of CABOMETYX into new geographic markets.
• Advancement of XB002 through clinical development.

What Are the Key Risks for EXEL?

Insider selling — insiders were net sellers of roughly $19.7M recently.

• Clinical trial failures for XL092 or XB002.
• Regulatory setbacks in obtaining approvals for new drugs or indications.
• Competition from other pharmaceutical companies in the oncology market.
• Patent expirations on key products.
• Negative impact from changes in healthcare regulations or reimbursement policies.

What Are the Growth Opportunities for EXEL?

• Expansion of CABOMETYX Indications: Exelixis has the opportunity to expand the use of CABOMETYX into new indications beyond renal cell carcinoma and medullary thyroid cancer. This includes exploring its efficacy in other solid tumors, potentially increasing its market reach and revenue. The market for solid tumor treatments is estimated to reach $400 billion by 2030, presenting a substantial growth opportunity for Exelixis.
• Advancement of XL092: XL092, an oral tyrosine kinase inhibitor targeting multiple kinases, represents a significant growth opportunity. Positive clinical trial results could lead to its approval for various cancer types, expanding Exelixis' pipeline and revenue streams. The Phase 3 trial results expected in late 2027 will be a key catalyst.
• Development of XB002: XB002, an antibody-drug conjugate targeting tissue factor (TF), offers potential in treating advanced solid tumors and non-Hodgkin's lymphoma. Successful clinical development and regulatory approval could position Exelixis in the growing market for ADCs, projected to reach $25 billion by 2028.
• Strategic Collaborations: Exelixis can leverage strategic collaborations with pharmaceutical companies to expand its research and development capabilities and access new markets. Collaborations with companies like Ipsen Pharma SAS and Takeda Pharmaceutical Company Ltd. have already proven beneficial, and further partnerships could accelerate the development and commercialization of new therapies.
• Geographic Expansion: Exelixis has the opportunity to expand its geographic presence beyond the United States and Japan. Entering new markets, particularly in Europe and Asia, could significantly increase its revenue and market share. The company's existing partnerships can facilitate this expansion, leveraging their established distribution networks and regulatory expertise.

What Are EXEL's Competitive Advantages?

• Proprietary drug formulations and intellectual property protection.
• Established brand recognition for CABOMETYX and COMETRIQ.
• Extensive research and development capabilities.
• Strategic collaborations with leading pharmaceutical companies.

What Does EXEL Do?

Exelixis, Inc., founded in 1994 and headquartered in Alameda, California, is an oncology-focused biotechnology company dedicated to discovering, developing, and commercializing innovative medicines for cancer treatment. The company's flagship products include CABOMETYX tablets, used for treating patients with advanced renal cell carcinoma who have previously undergone anti-angiogenic therapy, and COMETRIQ capsules, designed for patients with progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are derived from cabozantinib, a potent inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors, which play critical roles in tumor growth and metastasis. Exelixis also markets COTELLIC, an inhibitor of MEK, as part of a combination regimen for treating advanced melanoma, and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for hypertension treatment in Japan. The company's development pipeline includes XL092, an oral tyrosine kinase inhibitor targeting VEGF receptors, MET, AXL, MER, and other kinases; XB002, an antibody-drug conjugate targeting tissue factor (TF) for advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for advanced or metastatic solid tumors; and another iteration of XB002 for non-Hodgkin's lymphoma. Exelixis has established numerous research collaborations and license agreements with companies such as Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company, enhancing its research and development capabilities and expanding its market reach. Formerly known as Exelixis Pharmaceuticals, Inc., the company rebranded to Exelixis, Inc. in February 2000, reflecting its focused commitment to oncology.

What Products and Services Does EXEL Offer?

• Discovers new medicines for cancer treatment.
• Develops therapies targeting various types of cancer.
• Commercializes oncology drugs in the United States and Japan.
• Manufactures and markets CABOMETYX tablets for renal cell carcinoma.
• Produces and distributes COMETRIQ capsules for medullary thyroid cancer.
• Conducts clinical trials to evaluate the safety and efficacy of new drug candidates.
• Collaborates with other pharmaceutical companies to expand research and development efforts.

How Does EXEL Make Money?

• Develops and commercializes proprietary oncology drugs.
• Generates revenue through sales of CABOMETYX, COMETRIQ, COTELLIC, and MINNEBRO.
• Out-licenses certain rights to its products in specific territories.
• Collaborates with other companies to co-develop and co-commercialize therapies.

What Industry Does EXEL Operate In?

Exelixis operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The oncology market is experiencing significant growth, driven by an aging population and advancements in cancer diagnostics and treatments. Exelixis competes with major pharmaceutical companies and other biotechnology firms, including RVMD: Revolution Medicines, Inc. and MDGL: Madrigal Pharmaceuticals, Inc., in developing and commercializing cancer therapies. The company's focus on kinase inhibitors and antibody-drug conjugates positions it to capitalize on the growing demand for targeted cancer treatments.

Who Are EXEL's Key Customers?

• Patients with advanced renal cell carcinoma.
• Patients with progressive and metastatic medullary thyroid cancer.
• Patients with advanced melanoma.
• Patients with hypertension (in Japan).

Company Profile

Exelixis, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alameda, United States.

Return on equity for Exelixis, Inc. stands at 40.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 32.1%, showing how much profit it generates from its asset base. EXEL trades at a trailing price-to-earnings ratio of 17.46, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 6.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.0%, the inverse of the P/E and a quick read on earnings relative to price.

EXEL Valuation & Market Position

With a $14.5B market cap, Exelixis, Inc. sits in the large-cap segment of the market. Analyst price targets span from $46.00 to $56.00, with a consensus of $51.78. At the current price of $57.61, that implies roughly 10% downside from the consensus target. Relative to its peer group, EXEL's quantitative score of 98/100 is above the peer average of 68/100.

Quarterly Financial Performance: Exelixis, Inc.

Revenue for Exelixis, Inc. came in at $628.7M during Q2 FY2026, a 2.9% improvement versus the preceding quarter. The company recorded net income of $212.1M, with diluted EPS of $0.82. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, EXEL averaged $0.80 in diluted EPS.

Exelixis, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 15.92 places it in the safe zone, indicating low near-term bankruptcy risk.

Exelixis, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 20.9% above estimates on average.

Wall Street analysts project Exelixis, Inc. revenue of about $2.55B for fiscal 2027, with EPS near $3.51. The estimate reflects 13 contributing analysts.

Over the past six months, Exelixis, Inc. insiders filed 30 SEC Form 4 transactions — 17 sales and 13 purchases. On net that is roughly 314K shares disposed (about $19.7M), a signal worth weighing alongside the fundamentals.

EXEL Financials

EXEL Latest News

EXEL Analyst Consensus

EXEL MoonshotScore

Latest Exelixis, Inc. Analysis

EXEL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources